Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 389-400 , June 2009

Statins, ACE inhibitors and ARBs in cardiovascular disease

References 

  1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–2753
  2. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855–2864
  3. American Heart Association . 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002;
  4. Ledford DK, Espinoza LR. Immunologic aspects of cardiovascular disease. JAMA: The Journal of the American Medical Association. 1987;258:2974–2982
  5. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nature Reviews. Immunology. 2006;6:508–519
  6. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–1672
  7. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772–1778
  8. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462–2678
  9. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–1374
  10. Fox KA, Birkhead J, Wilcox R, et al. British Cardiac Society Working Group on the definition of myocardial infarction. Heart. 2004;90:603–609
  11. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Journal of the American College of Cardiology. 2007;50:2173–2195
  12. Capildeo R, Haberman S, Rose FC. The definition and classification of stroke. A new approach. The Quarterly Journal of Medicine. 1978;47:177–196
  13. Ovbiagele B, Kidwell CS, Saver JL. Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack. Stroke. 2003;34:919–924
  14. Jolicoeur EM, Ohman EM, Temple R, et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. American Heart Journal. 2008;155:435–444
  15. Pohjasvaara T, Mäntylä R, Ylikoski R, et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke. 2000;31:2952–2957
  16. Leskinen Y, Salenius JP, Lehtimäki T, et al. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. American Journal of Kidney Diseases. 2002;40:472–479
  17. Prugger C, Wellmann J, Heidrich J, et al. Cardiovascular risk factors and mortality in patients with coronary heart disease. European Journal of Epidemiology. 2008;
  18. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  19. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford, England). 2008;
  20. Krebs M, Krssak M, Nowotny P, et al. Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. The Journal of Clinical Endocrinology and Metabolism. 2001;86:2153–2160
  21. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty acids cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789
  22. Shafrir E, Raz I. Diabetes: mellitus or lipidus?. Diabetologia. 2003;46:433–440
  23. Tobert JA, Bell GD, Birtwell J, et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. The Journal of Clinical Investigation. 1982;69:913–919
  24. Tobert JA, Hitzenberger G, Kukovetz WR, et al. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis. 1982;41:61–65
  25. Hoeg JM, Brewer HB. 3-Hydroxy-3-methylglutaryl – coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA: The Journal of the American Medical Association. 1987;258:3532–3536
  26. Illingworth DR, Bacon S. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. The American Journal of Cardiology. 1987;60:33G–42G
  27. Moride Y, Hegele RA, Langer A, et al. Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. The Canadian Journal of Cardiology. 2008;24:293–300
  28. Neil HA, DeMicco DA, Luo D, et al., CARDS Study Investigators  Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29:2378–2384
  29. Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–1157
  30. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. Journal of Vascular Surgery. 2007;45:645–654discussion 653–654
  31. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485
  32. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2006;166:2307–2313
  33. Ridker PM, Fonseca FA, Genest J, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. The American Journal of Cardiology. 2007;100:1659–1664
  34. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. Journal of Cardiac Failure. 2006;12:664–674
  35. Gissi-Hf Investigators . Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–1239
  36. Kjekshus J, Apetrei E, Barrios V, et al., CORONA Group  Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine. 2007;357:2248–2261
  37. Nishikawa H, Miura S, Zhang B, et al. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coronary Artery Disease. 2002;13:377–381
  38. Borghi C, Veronesi M, Prandin MG, et al. Statins and blood pressure regulation. Current Hypertension Reports. 2001;3:281–288
  39. McFarlane SI, Muniyappa R, Francisco R, et al. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1451–1458
  40. Inami N, Nomura S, Shouzu A, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiology of Haemostasis and Thrombosis. 2007;36:1–8
  41. Kinlay S, Schwartz GG, Olsson AG, et al. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:142–147
  42. Vlachopoulos C, Aznaouridis K, Dagre A, et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. European Heart Journal. 2007;28:2102–2109
  43. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal. 2007;153:881–888
  44. Pignatelli P, Sanguigni V, Lenti L, et al. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Journal of Thrombosis and Haemostasis. 2007;5:1170–1178
  45. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. Journal of the American College of Cardiology. 2007;49:290–297
  46. Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology. 2006;17:S231–S235
  47. Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. Journal of the American College of Cardiology. 2006;48:1560–1566
  48. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology. 2006;48:396–401
  49. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Journal of the American College of Cardiology. 2006;47:332–337
  50. Macin SM, Perna ER, Farías EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. American Heart Journal. 2005;149:451–457
  51. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:168–174
  52. Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine. 2005;15:202–206
  53. Spring S, Simon R, van der Loo B, et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thrombosis and Haemostasis. 2008;99:182–189
  54. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. Journal of the American College of Cardiology. 2007;50:852–858
  55. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA: The Journal of the American Medical Association. 2007;297:1344–1353
  56. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. Journal of Cardiovascular Pharmacology. 2000;36:617–621
  57. Eichstädt HW, Eskötter H, Hoffman I, et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. The American Journal of Cardiology. 1995;76:122A–125A
  58. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519–2524
  59. Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2008;196:704–711
  60. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249–252
  61. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–933
  62. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA: The Journal of the American Medical Association. 1999;282:2340–2346
  63. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vascular Health and Risk Management. 2005;1:29–40
  64. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. The New England Journal of Medicine. 1999;341:70–76
  65. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine. 2005;352:1425–1435
  66. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA: The Journal of the American Medical Association. 2005;294:2437–2445
  67. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA: The Journal of the American Medical Association. 2001;285:1711–1718
  68. Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. European Heart Journal. 2002;23:1931–1937
  69. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA: The Journal of the American Medical Association. 2004;292:1307–1316
  70. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology. 2005;46:1417–1424
  71. Ovbiagele B, Saver JL. Intensive statin therapy after stroke or transient ischemic attack: a SPARCLing success?. Stroke. 2007;38:1110–1112
  72. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  73. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs. 2007;67(Suppl. 1):43–54
  74. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. Journal of the American College of Cardiology. 2005;46:1855–1862
  75. Josan K, McAlister FA. Cholesterol lowering for secondary prevention: what statin dose should we use?. Vascular Health and Risk Management. 2007;3:615–627
  76. Hennekens CH, Hollar D, Eidelman RS, et al. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Medscape General Medicine. 2006;8:54
  77. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  78. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. Clinical Pharmacokinetics. 2008;47:463–474
  79. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–2797
  80. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. Journal of Internal Medicine. 2006;260:305–319
  81. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension. 2007;50:596–599
  82. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219
  83. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research. 2000;87:E1–E9
  84. Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. The International Journal of Biochemistry & Cell Biology. 2006;38:737–751
  85. Rizzoni D, Agabiti Rosei E. Small artery remodeling in hypertension and diabetes. Current Hypertension Reports. 2006;8:90–95
  86. Connelly KA, Boyle AJ, Kelly DJ. Angiotensin II and the cardiac complications of diabetes mellitus. Current Pharmaceutical Design. 2007;13:2721–2729
  87. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. Journal of Hypertension. Supplement. 2006;24:S73–S80
  88. Ichihara A, Hayashi M, Hirota N, et al. Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells. Hypertension Research. 2003;26:915–921
  89. Apostolakis S, Krambovitis E, Vlata Z, et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators. Thrombosis Research. 2007;121:387–395
  90. Inukai T, Yoshida N, Wakabayashi S, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus. The American Journal of the Medical Sciences. 2005;329:222–227
  91. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054–2057
  92. Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. Journal of Hypertension. 2006;24:1809–1816
  93. Jia N, Okamoto H, Shimizu T, et al. A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression. Hypertension Research. 2003;26:737–742
  94. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England Journal of Medicine. 2000;342:145–153
  95. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  96. Solomon SD, Rice MM, Jablonski K, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26–31
  97. DREAM Trial Investigators , Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine. 2006;355:1551–1562
  98. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA: The Journal of the American Medical Association. 2002;288:2998–3007
  99. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  100. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669–685
  101. Rutherford JD, Pfeffer MA, Moyé LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation. 1994;90:1731–1738
  102. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. The New England Journal of Medicine. 1995;333:1670–1676
  103. ONTARGET Investigators , Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine. 2008;358:1547–1559
  104. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  105. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension. 2003;21:875–886
  106. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  107. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  108. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal of the American College of Cardiology. 2006;47:726–733
  109. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group . Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–760
  110. Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. European Journal of Heart Failure. 2004;6:937–945
  111. Diener HC, Sacco R, Yusuf S, Steering Committee , PRoFESS Study Group . Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovascular Diseases (Basel, Switzerland). 2007;23:368–380
  112. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  113. Khan NA, Hemmelgarn B, Herman RJ, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. The Canadian Journal of Cardiology. 2008;24:465–475
  114. Viberti G. Regression of albuminuria: latest evidence for a new approach. Journal of Hypertension. Supplement. 2003;21:S24–S28
  115. Hasslacher C, Kempe HP, Bostedt-Kiesel A. ACE inhibitors and diabetic nephropathy: clinical and experimental findings. The Clinical Investigator. 1993;71(5 Suppl.):S20–S24
  116. Parving HH, Andersen S, Jacobsen P, et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminars in Nephrology. 2004;24:147–157
  117. MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. American Journal of Kidney Diseases. 2006;48:8–20
  118. Deferrari G, Ravera M, Deferrari L, et al. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. Journal of the American Society of Nephrology. 2002;13(Suppl. 3):S224–S229
  119. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes & Metabolism. 2004;30:487–496
  120. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes & Metabolism. 2004;30:498–505
  121. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). Journal of the American College of Cardiology. 2004;44:E1–E211
  122. Canadian Cardiovascular Society , American Academy of Family Physicians , American College of Cardiology , American Heart Association , Antman EM, Hand M, et al 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2008;51:210–247
  123. AHA , ACC , National Heart, Lung, and Blood Institute , Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. Journal of the American College of Cardiology. 2006;47:2130–2139
  124. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. Journal of Cardiac Failure. 2008;14:181–188

PII: S1521-690X(08)00172-3

doi: 10.1016/j.beem.2008.12.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 389-400 , June 2009

Article Tools

* Image Usage & Resolution